[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482499":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":411,"collaborators":40,"id":413,"slug":414,"hasResults":415,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":40,"eligibilityCriteria":419,"healthyVolunteers":415,"sex":420,"minAge":421,"maxAge":40,"enrollmentInfo":422,"targetDuration":40,"studyType":425,"phases":426,"briefSummary":429,"conditions":430,"keywords":40,"overallStatus":54,"whyStopped":40,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":441},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: Zilovertamab vedotin","EXPERIMENTAL","Participants will receive zilovertamab vedotin 2mg\u002Fkg administered on Day 1 and Day 8 of each 3 week cycle (Q3W) until documented disease progression or any other discontinuation criterion is met.",[13],"Biological: Zilovertamab vedotin",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B: Pembrolizumab and MK-3120","Participants will receive MK-3120 up to 5mg\u002Fkg administered on Day 1, Day 15 and Day 29 of each 6 week cycle until documented disease progression or any other discontinuation criterion is met and 400mg pembrolizumab on Day 1 of each 6 week cycle for up to 17 cycles (up to \\~2 years).",[18,19],"Biological: Pembrolizumab","Biological: MK-3120",[21,29,36],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Zilovertamab vedotin","Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles",[9],[27,28],"MK-2140","VLS-101",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Pembrolizumab","Administered via IV infusion on Day 1 of each 6 week cycle.",[15],[34,35],"MK-3475","KEYTRUDA®",{"type":22,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"MK-3120","Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.",[15],null,[42],{"name":43,"affiliation":5,"role":44},"Medical Director","STUDY_DIRECTOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[52,70,82,93,106,119,132,144,157,170,183,195,210,225,234,249,263,275,287,302,314,329,342,351,360,375,387,402],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)","RECRUITING","Orange","California","92868","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-117.85311,33.78779,{"lat":64,"lon":63},[67],{"name":68,"role":48,"phone":69,"phoneExt":40,"email":40},"Study Coordinator","714-509-2371",{"facility":71,"status":54,"city":72,"state":56,"zip":73,"country":58,"countryCode":59,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"University of California San Francisco ( Site 1044)","San Francisco","94158",{"type":61,"coordinates":75},[76,77],-122.41942,37.77493,{"lat":77,"lon":76},[80],{"name":68,"role":48,"phone":81,"phoneExt":40,"email":40},"415-476-4616",{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":58,"countryCode":59,"cosmosGeoPoint":88,"geoPoint":92,"contacts":40},"Anschutz Cancer Pavilion ( Site 1017)","COMPLETED","Aurora","Colorado","80045",{"type":61,"coordinates":89},[90,91],-104.83192,39.72943,{"lat":91,"lon":90},{"facility":94,"status":54,"city":95,"state":96,"zip":97,"country":58,"countryCode":59,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"University of Chicago Medical Center ( Site 1037)","Chicago","Illinois","60637",{"type":61,"coordinates":99},[100,101],-87.65005,41.85003,{"lat":101,"lon":100},[104],{"name":68,"role":48,"phone":105,"phoneExt":40,"email":40},"855-702-8222",{"facility":107,"status":54,"city":108,"state":109,"zip":110,"country":58,"countryCode":59,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)","Indianapolis","Indiana","46202",{"type":61,"coordinates":112},[113,114],-86.15804,39.76838,{"lat":114,"lon":113},[117],{"name":68,"role":48,"phone":118,"phoneExt":40,"email":40},"888-600-4822",{"facility":120,"status":54,"city":121,"state":122,"zip":123,"country":58,"countryCode":59,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Siteman Cancer Center ( Site 1038)","St Louis","Missouri","63108",{"type":61,"coordinates":125},[126,127],-90.19789,38.62727,{"lat":127,"lon":126},[130],{"name":68,"role":48,"phone":131,"phoneExt":40,"email":40},"800-600-3606",{"facility":133,"status":54,"city":134,"state":134,"zip":135,"country":58,"countryCode":59,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Memorial Sloan Kettering Cancer Center ( Site 1031)","New York","10065",{"type":61,"coordinates":137},[138,139],-74.00597,40.71427,{"lat":139,"lon":138},[142],{"name":68,"role":48,"phone":143,"phoneExt":40,"email":40},"646-888-4770",{"facility":145,"status":54,"city":146,"state":147,"zip":148,"country":58,"countryCode":59,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Cleveland Clinic-Taussig Cancer Center ( Site 1036)","Cleveland","Ohio","44195",{"type":61,"coordinates":150},[151,152],-81.69541,41.4995,{"lat":152,"lon":151},[155],{"name":68,"role":48,"phone":156,"phoneExt":40,"email":40},"216-445-7728",{"facility":158,"status":54,"city":159,"state":160,"zip":161,"country":58,"countryCode":59,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"UPMC Hillman Cancer Center ( Site 1014)","Pittsburgh","Pennsylvania","15232",{"type":61,"coordinates":163},[164,165],-79.99589,40.44062,{"lat":165,"lon":164},[168],{"name":68,"role":48,"phone":169,"phoneExt":40,"email":40},"412-623-4759",{"facility":171,"status":54,"city":172,"state":173,"zip":174,"country":58,"countryCode":59,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Huntsman Cancer Institute ( Site 1041)","Salt Lake City","Utah","84112-5500",{"type":61,"coordinates":176},[177,178],-111.89105,40.76078,{"lat":178,"lon":177},[181],{"name":68,"role":48,"phone":182,"phoneExt":40,"email":40},"801-585-0155",{"facility":184,"status":84,"city":185,"state":186,"zip":187,"country":188,"countryCode":189,"cosmosGeoPoint":190,"geoPoint":194,"contacts":40},"Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)","Brisbane","Queensland","4029","Australia","AU",{"type":61,"coordinates":191},[192,193],153.02809,-27.46794,{"lat":193,"lon":192},{"facility":196,"status":54,"city":197,"state":198,"zip":199,"country":200,"countryCode":201,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Princess Margaret Cancer Centre ( Site 1106)","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":61,"coordinates":203},[204,205],-79.39864,43.70643,{"lat":205,"lon":204},[208],{"name":68,"role":48,"phone":209,"phoneExt":40,"email":40},"4169464501 2662",{"facility":211,"status":54,"city":212,"state":213,"zip":214,"country":215,"countryCode":216,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"FALP-UIDO ( Site 1151)","Santiago","Region M. de Santiago","7500921","Chile","CL",{"type":61,"coordinates":218},[219,220],-70.64827,-33.45694,{"lat":220,"lon":219},[223],{"name":68,"role":48,"phone":224,"phoneExt":40,"email":40},"56224205098",{"facility":226,"status":54,"city":212,"state":213,"zip":227,"country":215,"countryCode":216,"cosmosGeoPoint":228,"geoPoint":230,"contacts":231},"Bradford Hill ( Site 1155)","8420383",{"type":61,"coordinates":229},[219,220],{"lat":220,"lon":219},[232],{"name":68,"role":48,"phone":233,"phoneExt":40,"email":40},"+56229490970",{"facility":235,"status":54,"city":236,"state":237,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Rigshospitalet-Dept. of Oncology ( Site 1701)","Copenhagen","Capital Region","2100","Denmark","DK",{"type":61,"coordinates":242},[243,244],12.56553,55.67594,{"lat":244,"lon":243},[247],{"name":68,"role":48,"phone":248,"phoneExt":40,"email":40},"00 45 35 45 35 45",{"facility":250,"status":54,"city":251,"state":40,"zip":252,"country":253,"countryCode":254,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Rambam Health Care Campus-Oncology ( Site 1501)","Haifa","3109601","Israel","IL",{"type":61,"coordinates":256},[257,258],34.99928,32.81303,{"lat":258,"lon":257},[261],{"name":68,"role":48,"phone":262,"phoneExt":40,"email":40},"+972-4-7776234",{"facility":264,"status":54,"city":265,"state":40,"zip":266,"country":253,"countryCode":254,"cosmosGeoPoint":267,"geoPoint":271,"contacts":272},"Rabin Medical Center-Oncology ( Site 1504)","Petah Tikva","4941492",{"type":61,"coordinates":268},[269,270],34.88747,32.08707,{"lat":270,"lon":269},[273],{"name":68,"role":48,"phone":274,"phoneExt":40,"email":40},"972 393 78077",{"facility":276,"status":54,"city":277,"state":40,"zip":278,"country":253,"countryCode":254,"cosmosGeoPoint":279,"geoPoint":283,"contacts":284},"Sheba Medical Center-ONCOLOGY ( Site 1503)","Ramat Gan","5265601",{"type":61,"coordinates":280},[281,282],34.81065,32.08227,{"lat":282,"lon":281},[285],{"name":68,"role":48,"phone":286,"phoneExt":40,"email":40},"03-5304498",{"facility":288,"status":54,"city":289,"state":290,"zip":291,"country":292,"countryCode":293,"cosmosGeoPoint":294,"geoPoint":298,"contacts":299},"Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)","Milan","Lombardy","20133","Italy","IT",{"type":61,"coordinates":295},[296,297],9.18951,45.46427,{"lat":297,"lon":296},[300],{"name":68,"role":48,"phone":301,"phoneExt":40,"email":40},"+390223904449",{"facility":303,"status":54,"city":304,"state":40,"zip":305,"country":292,"countryCode":293,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)","Naples","80131",{"type":61,"coordinates":307},[308,309],14.26811,40.85216,{"lat":309,"lon":308},[312],{"name":68,"role":48,"phone":313,"phoneExt":40,"email":40},"00393331891929",{"facility":315,"status":54,"city":316,"state":317,"zip":318,"country":319,"countryCode":320,"cosmosGeoPoint":321,"geoPoint":325,"contacts":326},"Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)","Amsterdam","North Holland","1066 CX","Netherlands","NL",{"type":61,"coordinates":322},[323,324],4.88969,52.37403,{"lat":324,"lon":323},[327],{"name":68,"role":48,"phone":328,"phoneExt":40,"email":40},"+31 20 512 9111",{"facility":330,"status":54,"city":331,"state":40,"zip":332,"country":333,"countryCode":40,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"Severance Hospital, Yonsei University Health System ( Site 1903)","Seoul","03722","South Korea",{"type":61,"coordinates":335},[336,337],126.9784,37.566,{"lat":337,"lon":336},[340],{"name":68,"role":48,"phone":341,"phoneExt":40,"email":40},"+82222288138",{"facility":343,"status":54,"city":331,"state":40,"zip":344,"country":333,"countryCode":40,"cosmosGeoPoint":345,"geoPoint":347,"contacts":348},"Asan Medical Center ( Site 1901)","05505",{"type":61,"coordinates":346},[336,337],{"lat":337,"lon":336},[349],{"name":68,"role":48,"phone":350,"phoneExt":40,"email":40},"+82230105977",{"facility":352,"status":54,"city":331,"state":40,"zip":353,"country":333,"countryCode":40,"cosmosGeoPoint":354,"geoPoint":356,"contacts":357},"Samsung Medical Center ( Site 1902)","06351",{"type":61,"coordinates":355},[336,337],{"lat":337,"lon":336},[358],{"name":68,"role":48,"phone":359,"phoneExt":40,"email":40},"+82234103459",{"facility":361,"status":54,"city":362,"state":363,"zip":364,"country":365,"countryCode":366,"cosmosGeoPoint":367,"geoPoint":371,"contacts":372},"Hospital Universitari Vall d'Hebron ( Site 1767)","Barcelona","Catalonia","08035","Spain","ES",{"type":61,"coordinates":368},[369,370],2.15899,41.38879,{"lat":370,"lon":369},[373],{"name":68,"role":48,"phone":374,"phoneExt":40,"email":40},"+34934894158",{"facility":376,"status":54,"city":377,"state":40,"zip":378,"country":365,"countryCode":366,"cosmosGeoPoint":379,"geoPoint":383,"contacts":384},"Hospital Clinico San Carlos ( Site 1765)","Madrid","28040",{"type":61,"coordinates":380},[381,382],-3.70256,40.4165,{"lat":382,"lon":381},[385],{"name":68,"role":48,"phone":386,"phoneExt":40,"email":40},"+34913303546",{"facility":388,"status":54,"city":389,"state":390,"zip":391,"country":392,"countryCode":393,"cosmosGeoPoint":394,"geoPoint":398,"contacts":399},"St Bartholomew's Hospital ( Site 1206)","London","London, City of","EC1A 7BE","United Kingdom","UK",{"type":61,"coordinates":395},[396,397],-0.12574,51.50853,{"lat":397,"lon":396},[400],{"name":68,"role":48,"phone":401,"phoneExt":40,"email":40},"+44 0203 416 5000",{"facility":403,"status":54,"city":389,"state":390,"zip":404,"country":392,"countryCode":393,"cosmosGeoPoint":405,"geoPoint":407,"contacts":408},"ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)","SW3 6JJ",{"type":61,"coordinates":406},[396,397],{"lat":397,"lon":396},[409],{"name":68,"role":48,"phone":410,"phoneExt":40,"email":40},"+44 20 7352 8171",{"type":412,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100482499","phase-1-a-substudy-of-investigational-agents-in-programmed-cell-death-1ligand-1-pd-1l1-refractory-locally-advanced-or-metastatic-urothelial-carcinoma-muc-mk-3475-04a-100482499",false,"NCT05562830","A Substudy of Investigational Agents in Programmed Cell Death-1\u002FLigand 1 (PD-1\u002FL1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","A Phase 1\u002F2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1\u002FL1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A","Inclusion Criteria:\n\nThe main inclusion and exclusion criteria include but are not limited to the following:\n\n* Histologically or cytologically confirmed diagnosis of locally advanced\u002Funresectable or mUC of the renal pelvis, ureter (upper urinary tract), bladder, or urethra.\n* Arm A: PD-1\u002FL1 refractory locally advanced or mUC as evidenced by: EITHER disease progression while on treatment or after treatment with an anti-PD-1\u002FL1 monoclonal antibody (mAb) for locally advanced\u002Funresectable or mUC administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies OR disease recurrence while on treatment or after treatment with an anti-PD-1\u002FL1 mAb for muscle-invasive urothelial carcinoma (MIUC) administered as monotherapy.\n* Arm A: Participants must provide an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion demonstrating UC, not previously irradiated, and adequate for biomarker evaluation.\n* Arm B: PD-1\u002FL1 refractory locally advanced or mUC as evidenced by: EITHER disease progression after treatment with an anti-PD-1\u002FL1 mAb for locally advanced\u002Funresectable or mUC administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies; OR disease recurrence after treatment with an anti-PD-1\u002FL1 mAb for MIUC administered as monotherapy or in combination with other checkpoint therapies \\>12 months after last dose of treatment with an anti-PD-1\u002FL1 mAb.\n* Arm B: Participants must provide an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion from a metastatic site or from a primary tumor that has become locally advanced and not previously irradiated.\n\nExclusion Criteria:\n\n* Known additional nonurothelial malignancy that is progressing or has required active treatment within 3 years prior to study randomization\u002Fallocation.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization\u002Fallocation.\n* Active infection requiring systemic therapy.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Known history of human immunodeficiency virus (HIV).\n* Known history of hepatitis B or known hepatitis C virus infection.","ALL","18 Years",{"count":423,"type":424},48,"ESTIMATED","INTERVENTIONAL",[427,428],"PHASE1","PHASE2","This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1\u002Fligand 1 (PD-1\u002FL1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.",[431],"Urothelial Carcinoma","2026-05-26",{"date":434,"type":435},"2026-05-27","ACTUAL",{"date":437,"type":435},"2022-11-16",{"date":439,"type":424},"2029-02-26",{"name":5,"class":6},28]